Literature DB >> 28042507

MicroRNA-497 suppresses cell proliferation and induces apoptosis through targeting PBX3 in human multiple myeloma.

Tianhua Yu1, Xuanhe Zhang2, Lirong Zhang3, Yali Wang1, Hongjuan Pan1, Zhihua Xu4, Xiaochuan Pang5.   

Abstract

Aberrant expression of microRNA-497 (miRN-497) is implicated in development and progression of multiple types of cancers. However, the biological function and underlying mechanism of miR-497 in multiple myeloma (MM) remains unclear. Thus, we studied the potential biological roles of miR-497 in MM. The expression of miR-497 was examined in multiple myeloma and normal plasma cells by qRT-PCR. Biological functions of miR-497 were analyzed using cell proliferation, colony formation, cell cycle, apoptosis and luciferase assays in vitro, as well as via tumorigenicity in vivo analysis. Here, we observed reduced expression of miR-497 in MM plasma samples and cell lines. Ectopic expression of miR-497 dramatically suppressed cell proliferation and clonogenicity, as well as induced cell arrest at G0/G1 stage and apoptosis in vitro. Mechanistic investigation assays showed that Pre-B-cellleukemia transcription factor 3 (PBX3) was a novel and direct downstream target of miR-497. Interestingly, overexpression of PBX3 partially reverted the effect of miR-497 in MM cells. In xenograft model, overexpression of miR-497 inhibited tumorigenicity by repressing PBX3. These findings collectively suggested that miR-497 functioned as tumor suppressor in MM by directly targeting PBX3, supporting its utility as a novel and potential therapeutic agent for MM therapy.

Entities:  

Keywords:  PBX3; apoptosis; miR-497; multiple myeloma; proliferation

Year:  2016        PMID: 28042507      PMCID: PMC5199761     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  38 in total

Review 1.  Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

Authors:  Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2011-11       Impact factor: 6.261

2.  Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

Authors:  Zejuan Li; Hao Huang; Yuanyuan Li; Xi Jiang; Ping Chen; Stephen Arnovitz; Michael D Radmacher; Kati Maharry; Abdel Elkahloun; Xinan Yang; Chunjiang He; Miao He; Zhiyu Zhang; Konstanze Dohner; Mary Beth Neilly; Colles Price; Yves A Lussier; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Lars Bullinger; Peter J M Valk; Ruud Delwel; Bob Lowenberg; Paul P Liu; Guido Marcucci; Clara D Bloomfield; Janet D Rowley; Jianjun Chen
Journal:  Blood       Date:  2012-01-17       Impact factor: 22.113

Review 3.  microRNA functions.

Authors:  Natascha Bushati; Stephen M Cohen
Journal:  Annu Rev Cell Dev Biol       Date:  2007       Impact factor: 13.827

4.  MicroRNA-497 targets hepatoma-derived growth factor and suppresses human prostate cancer cell motility.

Authors:  Deyao Wu; Xiaobing Niu; Huixing Pan; Zichun Zhang; Yunfeng Zhou; Ping Qu; Jian Zhou
Journal:  Mol Med Rep       Date:  2016-01-11       Impact factor: 2.952

5.  MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer.

Authors:  Wei Wang; Fang Ren; Qinghua Wu; Dazhi Jiang; Hongjun Li; Huirong Shi
Journal:  Oncol Rep       Date:  2014-08-22       Impact factor: 3.906

6.  MicroRNA-497 suppresses osteosarcoma tumor growth in vitro and in vivo.

Authors:  Liang Ge; Baisong Zheng; Minghe Li; Liang Niu; Zhihong Li
Journal:  Oncol Lett       Date:  2016-01-29       Impact factor: 2.967

Review 7.  Advances in biology and therapy of multiple myeloma.

Authors:  Sophie Barillé-Nion; Bart Barlogie; Régis Bataille; P Leif Bergsagel; Joshua Epstein; Robert G Fenton; Joth Jacobson; W Michael Kuehl; John Shaughnessy; Guido Tricot
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2003

Review 8.  MicroRNAs in cell proliferation, cell death, and tumorigenesis.

Authors:  H-W Hwang; J T Mendell
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

Review 9.  Role of micro-RNAs in drug resistance of multiple myeloma.

Authors:  Jahangir Abdi; Hou Jian; Hong Chang
Journal:  Oncotarget       Date:  2016-09-13

10.  The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster.

Authors:  Toshihiko Itesako; Naohiko Seki; Hirofumi Yoshino; Takeshi Chiyomaru; Takeshi Yamasaki; Hideo Hidaka; Tomokazu Yonezawa; Nijiro Nohata; Takashi Kinoshita; Masayuki Nakagawa; Hideki Enokida
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

View more
  11 in total

1.  miR-495 inhibits proliferation, migration, and invasion and induces apoptosis via inhibiting PBX3 in melanoma cells.

Authors:  Guangxiong Chen; Yijie Xie
Journal:  Onco Targets Ther       Date:  2018-04-05       Impact factor: 4.147

2.  Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer.

Authors:  Tiphaine de Foucher; Maria Sbeih; Jenifer Uzan; Sofiane Bendifallah; Marine Lefevre; Nathalie Chabbert-Buffet; Selim Aractingi; Catherine Uzan; Issam Abd Alsalam; Rana Mitri; Romain H Fontaine; Emile Daraï; Bassam Haddad; Céline Méhats; Marcos Ballester; Geoffroy Canlorbe; Cyril Touboul
Journal:  J Transl Med       Date:  2018-05-21       Impact factor: 5.531

3.  MG132 inhibits the expression of PBX3 through miRNAs by targeting Argonaute2 in hepatoma cells.

Authors:  Daiyong Mou; Xiaodan Yang; Sheng Li; Wei Zhao; Meng Li; Maoji Zhao; Nasser Hadal Alotaibi; Zhiqian Zhang; Min Tang; Khalid Saad Alharbi; Joob Bahman; Syed Nasir Abbas Bukhari; Cristina Dézlla
Journal:  Saudi J Biol Sci       Date:  2020-06-16       Impact factor: 4.219

4.  Increased expression of miR-27 predicts poor prognosis and promotes tumorigenesis in human multiple myeloma.

Authors:  Feifei Che; Chunqian Wan; Jingying Dai; Jiao Chen
Journal:  Biosci Rep       Date:  2019-04-09       Impact factor: 3.840

Review 5.  Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.

Authors:  Amro M Soliman; Teoh Seong Lin; Pasuk Mahakkanukrauh; Srijit Das
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

6.  Prognostic Role of MicroRNA-497 In Cancer Patients: A Meta-analysis.

Authors:  Jiaxi Feng; Xi Gu; Liyang Liu; Ming Lu; Xiang Ma; Yang Cao; Rongjiang Jiang; Baolin Wang; Qinghong Zhao
Journal:  J Cancer       Date:  2018-09-07       Impact factor: 4.207

7.  PBX3/MEK/ERK1/2/LIN28/let-7b positive feedback loop enhances mesenchymal phenotype to promote glioblastoma migration and invasion.

Authors:  Xiupeng Xu; Zhongyuan Bao; Yinlong Liu; Kuan Jiang; Tongle Zhi; Dong Wang; Liang Fan; Ning Liu; Jing Ji
Journal:  J Exp Clin Cancer Res       Date:  2018-07-17

8.  Up-regulation of microRNA-497 inhibits the proliferation, migration and invasion but increases the apoptosis of multiple myeloma cells through the MAPK/ERK signaling pathway by targeting Raf-1.

Authors:  Cheng-Yu Ye; Cui-Ping Zheng; Wei-Wei Ying; Shan-Shan Weng
Journal:  Cell Cycle       Date:  2018-12-11       Impact factor: 4.534

Review 9.  Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin.

Authors:  Martina Ghetti; Ivan Vannini; Clelia Tiziana Storlazzi; Giovanni Martinelli; Giorgia Simonetti
Journal:  Mol Cancer       Date:  2020-03-30       Impact factor: 27.401

10.  MicroRNA-497 elevation or LRG1 knockdown promotes osteoblast proliferation and collagen synthesis in osteoporosis via TGF-β1/Smads signalling pathway.

Authors:  ZhengTao Gu; DengHui Xie; CaiQiang Huang; Rui Ding; RongKai Zhang; QingChu Li; ChuangXin Lin; YiYan Qiu
Journal:  J Cell Mol Med       Date:  2020-09-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.